NCT07497503
A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 8 words Show 5 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Sep 30, 2026 to Oct 7, 2026
- Study completion date changed from estimate of Oct 14, 2026 to Oct 21, 2026
- Secondary endpoints: details revised at 5 of 12 entries
- Site details revised
- Minor Primary completion pushed from Jun 10, 2026 to Sep 30, 2026
- Study completion pushed from Jun 24, 2026 to Oct 14, 2026
Notable Recruitment openedv2 Show 6 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 8 words
- Primary completion date: May 29, 2026 to Jun 10, 2026
- Study completion date: Jun 11, 2026 to Jun 24, 2026
- Secondary endpoints: details revised at 4 of 12 entries
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Maximum Plasma Concentration (Cmax) of B-3E07
Timeframe: Treatment Periods 1 and 2: Day 1 - Pre-dose and up to 6 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) of B-3E07
Timeframe: Treatment Periods 1 and 2: Day 1 - Pre-dose and up to 6 hours post-dose
Cmax of Forsteo®
Timeframe: Treatment Periods 1 and 2: Day 1 - Pre-dose and up to 6 hours post-dose
AUC 0-inf of Forsteo®
Timeframe: Treatment Periods 1 and 2: Day 1 - Pre-dose and up to 6 hours post-dose
Secondary (12)
Area Under the Plasma Concentration-time Curve up to Time t (AUC 0-t) of B-3E07 and Forsteo®
Time to Attain Maximal Plasma Concentration (Tmax) of B-3E07 and Forsteo®
Terminal Elimination Half-life (t1/2) of B-3E07 and Forsteo®
Volume of Distribution (Vz/F) of B-3E07 and Forsteo®
Apparent Clearance (CL/F) of B-3E07 and Forsteo®
Show 7 moreShow less
Maximum Observed Effect (Emax) of B-3E07 and Forsteo®
Area Under the Effect-time Curve to the Last Measurable Time Point (AUEC 0-t) of B-3E07 and Forsteo®
Time to Attain Maximal Serum Concentration (Tmax) of B-3E07 and Forsteo®
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of Participants With Injection Site Reactions
Number of Participants With Clinically Significant Changes in Vital Signs, 12-lead Electrocardiograph (ECG), Physical Examinations, and Laboratory Test Results
Percentage of Participants With Positive Antidrug antibodies (ADA) and ADA Titers to B-3E07 and Forsteo®
Arms and interventions
Sequence 1: B-3E07 Followed by Forsteo ®Experimental
Participants will receive the B-3E07 as a single subcutaneous (SC) injection on Day 1 of Period 1 followed by the Forsteo® on Day 1 of Period 2. There will be a 14-day washout between each dosing (Day 1 of each period) and a follow-up of 14-days after the last dose.
Sequence 2: Forsteo® Followed by B-3E07Active comparator
Participants will receive the Forsteo® as a single SC injection on Day 1 of Period 1 followed by the B-3E07 on Day 1 of Period 2. There will be a 14-day washout between each dosing (Day 1 of each period) and a follow-up of 14-day after the last dose.
Biologicals: Forsteo®, B-3E07
Sites
1 site in 1 country
- Veritus ResearchBayswater, Victoria, Australia